European Medicines Agency Fast-Tracks Pancreatic Cancer Drug Review

The European Medicines Agency (EMA) has initiated an accelerated review process for daraxonrasib, an experimental oral treatment for pancreatic cancer. This expedited assessment is due to the drug's orphan medicinal product status and its high priority under the Cancer Medicines Pathfinder project, addressing a significant medical need. The phased review aims to speed up access to potential new therapies for this challenging disease.